Maravai (MRVI) CFO has 65,584 shares withheld for RSU tax
Maravai Lifesciences Holdings CFO Rajesh Asarpota reported a routine disposition of 65,584 Class A Common Stock shares. These shares were withheld at $6.39 each to cover tax obligations upon the vesting of restricted stock unit awards. As a result, Asarpota now directly holds 434,416 shares of Maravai Lifesciences Class A Common Stock.
ETFs Investing in Maravai Lifesciences Holdings, Inc. Class A Stocks
This article provides a list of Exchange Traded Funds (ETFs) that hold Maravai Lifesciences Holdings, Inc. Class A stocks, sorted by market value. It details various ETFs including their market value, weight, issuer, management style, focus, expense ratio, AUM, price change, relative volume, and 3-year NAV total return. The information aims to help investors find ETFs that offer broader investment opportunities with reduced risk compared to direct stock investments.
Millennium Management reports >5% stake then falls below 5% in MRVI (MRVI)
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander reported acquiring over a 5% beneficial ownership stake in Maravai LifeSciences Holdings, Inc. (MRVI) on June 23, 2026, via a Schedule 13G filing. However, by the filing date, they had ceased to be beneficial owners of more than 5%, with their reported shared voting and dispositive power covering 6,900,258 shares, representing 4.7% of the Class A common stock.
Price to earnings forward of Maravai Lifesciences Holdings, Inc. Class A – SWB:MAR
This page displays the "Price to earnings forward" metric for Maravai Lifesciences Holdings, Inc. Class A, traded on the Stuttgart Stock Exchange under the symbol MAR. The primary content consists of various navigation links and footer information from the TradingView platform, with the specific financial data for MAR not visibly displayed in this snippet. The article functions as a placeholder or a partially loaded page focusing on the particular financial metric for the given company.
MAR Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Maravai Lifesciences Holdings, Inc. (MAR) stock for 2027, based on analyst opinions. It details the company's financial performance, including recent earnings and revenue, and addresses frequently asked questions about its stock, dividends, and employment figures.
MAR Forecast — Price Target — Prediction for 2027
This article provides a forecast for Maravai Lifesciences Holdings, Inc. Class A (MAR) stock, including analyst price targets, past earnings, and revenue data. It also covers frequently asked questions about the company's ticker, highest/lowest prices, earnings reports, dividends, number of employees, and EBITDA. The information aims to help investors understand the stock's potential future performance.
Maravai Lifesciences Holdings, Inc. Class A Actuals & Estimates (NASDAQ:MRVI)
This article provides key financial metrics and analyst forecasts for Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI). It details the company's stock performance, market capitalization, earnings, revenue, and other financial data, highlighting recent fluctuations and future estimates. The content also addresses frequently asked questions regarding MRVI's stock, including its price, volatility, and dividend policy.
Millennium (MRVI) reports 7.32M shared stake, 4.96% as of Jun 16, 2026
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander filed a Schedule 13G for Maravai LifeSciences Holdings, Inc. (MRVI). The filing indicates shared beneficial ownership of 7,323,520 Class A common shares, representing 4.96% as of June 16, 2026. Although the reporting persons briefly held over 5%, they ceased to be beneficial owners of more than 5% by the filing date.
Maravai LifeSciences general counsel Oreshack sells $253,999 shares
Kurt Oreshack, General Counsel at Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), recently sold 50,000 shares of the company's Class A Common Stock for approximately $253,999. These sales were conducted under a Rule 10b5-1 trading plan and occurred on June 9 and 10, 2026, with prices ranging from $5.06 to $5.10 per share. Oreshack now directly holds 335,767 shares, and the sales occurred as the stock trades near its overvalued estimate.
Maravai (NASDAQ: MRVI) General Counsel sells 50,000 shares under 10b5-1 plan
Maravai Lifesciences' General Counsel, Kurt Oreshack, sold a total of 50,000 shares of Class A Common Stock through open-market transactions on June 9 and June 10, 2026. These sales, totaling $254,000, were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 10, 2026. Following these transactions, Oreshack directly holds 335,767 shares of MRVI stock.
Maravai Lifesciences director gifts 92,586 shares | MRVI Insider Trading
Maravai Lifesciences Holdings director Gregory T. Lucier reported gifting 92,586 shares of Class A common stock on June 9, 2026. The gifts were made in two bona fide transfers of 46,293 shares each at $0.00 per share. Following these transactions, Lucier directly holds 155,123 shares and indirectly holds 156,077 shares through a family partnership.
MRVI SEC Filings - Maravai Lifesciences Holdings, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Maravai Lifesciences Holdings (MRVI) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event filings (8-K), and insider trading forms. Recent filings detail director equity awards, a CFO transition, and internal reclassification of ownership. Each filing is accompanied by AI-generated summaries, impact scoring, and sentiment analysis for investors and traders.
Kurt Oreshack notifies sale of 25,000 MRVI Class A shares (NASDAQ: MRVI)
Kurt Oreshack has filed a Form 144 to sell 25,000 Class A shares of Maravai Lifesciences Holdings, Inc. (MRVI). The filing, dated June 10, 2026, indicates an aggregate amount of $127,500.00 and notes that the securities originated from Restricted Stock Vesting on January 15, 2025. This action signals an intent to sell a significant block of shares by an insider.
Maravai (MRVI) brokered sale notice: 25,000 Class A shares via Fidelity
Maravai LifeSciences (MRVI) has filed a Form 144, indicating an intent to sell 25,000 Class A common shares through Fidelity Brokerage Services LLC on NASDAQ. The filing details previous acquisitions of these shares through restricted stock vesting and ESPP purchases. This is a routine notice required for the planned disposal of restricted or control securities under Rule 144.
Maravai LifeSciences (MRVI) shareholders approve directors, auditor and pay at 2026 meeting
Maravai LifeSciences Holdings, Inc. announced the results of its 2026 Annual Meeting of Shareholders. During the meeting, shareholders elected three directors to three-year terms, ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2026, and approved on a non-binding advisory basis the compensation of the named executive officers. A quorum was established with 236,082,968 shares represented.
Maravai (MRVI) director granted 46,293 restricted stock units
Maravai LifeSciences Holdings director Gregory T. Lucier was granted 46,293 restricted stock units of Class A Common Stock on May 26, 2026, with a grant price of $0.00. This award, under the 2020 Omnibus Incentive Plan, vests in full on the earlier of one year from the grant date or the 2027 annual meeting. Following this transaction, Lucier directly holds 201,416 shares and indirectly holds 109,784 shares through a family partnership; the Form 4/A was filed to correct a previously reported purchase price.
Maravai (MRVI) director Susannah Gray receives 46,293-share stock unit award
Maravai LifeSciences Holdings, Inc. director Susannah Gray was granted 46,293 restricted stock units (RSUs) of Class A Common Stock. This award, made under the 2020 Omnibus Incentive Plan, increased her direct holdings to 216,200 shares. The RSUs will vest in full after one year from the grant date of May 26, 2026, or at the 2027 annual meeting, whichever comes first.
[Form 4] MARAVAI LIFESCIENCES HOLDINGS, INC. Insider Trading Activity
Maravai LifeSciences (MRVI) director Gregory T. Lucier reported an acquisition of 46,293 shares of Class A Common Stock through restricted stock units (RSUs) at a reference price of $4.38 per share. This RSU award, granted under the 2020 Omnibus Incentive Plan, vests fully on the earlier of one year from May 26, 2026, or the 2027 annual stockholders' meeting. Following this transaction, Lucier directly holds 201,416 shares and indirectly owns 109,784 shares via a family partnership.
Maravai LifeSciences (MRVI) director receives 46,293-share RSU award
MARAVAI LIFESCIENCES HOLDINGS, INC. director R. Andrew Eckert was granted 46,293 restricted stock units (RSUs) of Class A common stock as an equity compensation award on May 26, 2026. These RSUs were issued at no cost and will vest fully on the earlier of one year from the grant date or the company's 2027 annual meeting of stockholders. Following this transaction, Eckert directly holds 412,183 shares of Class A common stock in Maravai LifeSciences.
RSU grant to GTCR-affiliated entity via Maravai (MRVI) director
Maravai LifeSciences Holdings director Sean Laurence Cunningham was awarded a 46,293-share Restricted Stock Unit (RSU) grant, vesting on the earlier of one year from May 26, 2026, or the company's 2027 annual meeting. These securities are held for the benefit of a GTCR-affiliated entity, with Cunningham disclaiming pecuniary interest. Following this grant, his reported direct holdings in Maravai increased to 184,348 shares.
Maravai (MRVI) director Mihas receives 46,293 RSUs held for GTCR-affiliated entity
Maravai LifeSciences Holdings, Inc. director Constantine S. Mihas was granted 46,293 restricted stock units (RSUs) of Class A common stock on May 26, 2026, under the company's 2020 Omnibus Incentive Plan. These RSUs vest fully on the earlier of one year from the grant date or the 2027 annual stockholders’ meeting. Mihas holds these securities for a GTCR-affiliated entity and disclaims personal pecuniary interest, with total reported holdings for the entity now at 184,348 shares or units.
Maravai (MRVI) director awarded 46,293 RSUs in equity grant
Maravai LifeSciences (MRVI) director John A. DeFord was granted 46,293 restricted stock units (RSUs) on May 26, 2026. These RSUs, awarded under the company’s 2020 Omnibus Incentive Plan, will vest fully on the earlier of one year from the grant date or the 2027 annual stockholders' meeting. Following this grant, DeFord directly holds 205,478 shares of Class A Common Stock in the company.
Maravai Lifesciences (NASDAQ: MRVI) counsel gets 776 ESPP shares
Maravai LifeSciences Holdings, Inc.'s General Counsel, Kurt Oreshack, acquired 776 shares of Class A Common Stock at $2.84 per share through the company’s 2020 Employee Stock Purchase Plan. This transaction, exempt under Rule 16b-3, increased Oreshack's direct holdings to 385,767 shares of Class A Common Stock. The acquisition is noted as a routine compensation-related event rather than an open-market trade.
Maravai (MRVI) officer granted 5,006 ESPP shares at $1.79
Maravai LifeSciences Holdings insider Christine Dolan acquired 5,006 shares of Class A common stock at $1.79 per share through the company's 2020 Employee Stock Purchase Plan. This transaction, exempt under Rule 16b-3, increases Dolan's direct holdings to 425,318 shares and is considered a routine, compensation-related purchase rather than an open-market trade.
Maravai LifeSciences Q1 Turnaround Spurs Rethink Of CleanCap Driven Outlook
Maravai LifeSciences Holdings (NasdaqGS:MRVI) reported a significant Q1 2026 turnaround with a 41% revenue jump, narrowed net loss, and positive Adjusted EBITDA, driven by a large CleanCap vaccine order and debt reduction. The strong performance has led to a re-evaluation of the company's risk profile, with the stock price increasing substantially over the past year. Investors are now focused on whether this trend is sustainable or a one-off event.
12 West Capital Amends 13G, Holds 7.26M Shares in Maravai (MRVI)
12 West Capital Management and Joel Ramin have filed an amended 13G, reporting beneficial ownership of 7,260,195 shares of Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI), which represents a 4.9% stake in the company. This percentage is calculated based on 146,383,162 shares outstanding as of February 19, 2026. The filing indicates shared voting and dispositive power over these shares, and it is considered a neutral filing as the stake is below the 5% reporting threshold for different obligations.
Stuart Feldman-led group reports 9.21% stake in Maravai (MRVI)
A group led by Stuart Feldman has filed an amended Schedule 13G/A, disclosing a passive beneficial ownership of 13,488,799 shares of Maravai LifeSciences Holdings, Inc. Class A common stock, representing 9.21% of the class. Stuart Feldman individually holds 10,337,680 shares (7.06%). The filing details the sole voting and dispositive power for each member of the group, which also includes entities like Hudson View Holdings LLC and individuals like Matthew Barkoff and Joshua Wool.
Millennium group lists 4.9% holding in Maravai (NASDAQ: MRVI) on 13G
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G reporting a shared voting and dispositive power over 7,228,864 shares of Maravai LifeSciences Holdings, Inc. Class A Common Stock, which represents a 4.9% stake. The filing indicates they had briefly exceeded 5% beneficial ownership on May 6, 2026, but were below that threshold by the filing date, with a Joint Filing Agreement dated May 11, 2026. This is a passive investment disclosure, as indicated by the use of Schedule 13G.
Maravai LifeSciences (NASDAQ: MRVI) boosts Q1 revenue, cuts debt
Maravai LifeSciences reported significantly improved financial results for Q1 2026, with revenue increasing by 40.5% to $65.8 million, driven largely by its TriLink segment and $14.3 million in CleanCap® COVID-19 vaccine orders. The net loss narrowed to $6.4 million, and Adjusted EBITDA turned profitable at $20.3 million, aided by a 2025 Corporate Realignment Plan that reduced operating expenses. The company also voluntarily prepaid $50.0 million of its Term Loan, reducing long-term debt to $242.9 million by quarter-end.
Maravai LifeSciences Reports First Quarter 2026 Financial Results
Maravai LifeSciences (NASDAQ: MRVI) reported strong first-quarter 2026 financial results, with total revenue up 41% year-over-year to $65.8 million, driven by demand in its TriLink base business and high-volume CleanCap orders. The company achieved positive free cash flow of $4.2 million and significantly increased its full-year 2026 revenue and Adjusted EBITDA guidance. These results reflect improved operational efficiency and a confident outlook for sustained profitable growth.
Maravai LifeSciences Reports First Quarter 2026 Financial Results
Maravai LifeSciences announced strong first-quarter 2026 financial results, with total revenue up 41% to $65.8 million and Adjusted EBITDA reaching $20.3 million. The company returned to positive free cash flow, generating $4.2 million, and raised its full-year 2026 revenue and Adjusted EBITDA guidance due to improving demand in its core TriLink business and operational efficiencies. TriLink's base non-COVID revenue grew 15% year-over-year, contributing significantly to the overall growth.
COVID vaccine orders help Maravai raise 2026 revenue targets
Maravai LifeSciences reported a 41% increase in Q1 2026 revenue to $65.8 million, driven largely by $14.3 million in high-volume CleanCap orders for commercial COVID vaccine programs. This strong performance led the company to raise its full-year 2026 revenue guidance to $205.0 million - $215.0 million and Adjusted EBITDA guidance to $30.0 million - $32.0 million. The CEO highlighted improving demand in the core TriLink base business and disciplined cost management contributing to meaningful EBITDA expansion and positive free cash flow.
Maravai (NASDAQ: MRVI) lifts 2026 outlook after 41% Q1 revenue surge
Maravai LifeSciences (NASDAQ: MRVI) reported a strong first quarter in 2026, with revenue surging 40.5% to $65.8 million, driven by its TriLink segment and CleanCap orders. The company significantly improved profitability, narrowing its net loss and achieving positive Adjusted EBITDA and free cash flow. Consequently, Maravai raised its full-year 2026 guidance for both revenue and Adjusted EBITDA, citing improved demand and operational efficiency.
Levi & Korsinsky Reminds Maravai LifeSciences Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 - MRVI
Levi & Korsinsky reminds investors of a pending class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI). The lawsuit alleges that Maravai made false statements and concealed issues related to revenue recognition and overstated goodwill between August 7, 2024, and February 24, 2025. Investors who suffered losses during this period are encouraged to learn about their rights to potentially recover losses, with a lead plaintiff deadline of May 5, 2025.
[Form 4] MARAVAI LIFESCIENCES HOLDINGS, INC. Insider Trading Activity
Christine Dolan, an officer at MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI), reported a routine tax-withholding transaction. On March 16, 2026, 28,661 shares of Class A common stock were withheld at $3.08 per share to cover tax obligations related to the vesting of restricted stock units. Following this disposition, Dolan directly holds 420,312 shares of Class A common stock.
Maravai (MRVI) General Counsel has 39,976 shares withheld for taxes
Maravai Lifesciences Holdings General Counsel Kurt Oreshack had 39,976 shares of Class A common stock withheld at $3.08 per share to cover tax obligations related to the vesting of restricted stock units. This transaction was a routine tax-withholding and not an open-market sale. Following this non-market disposition, Oreshack directly holds 384,991 shares of Maravai stock.
After $231M loss, Maravai targets $200M+ in 2026 revenue
Maravai LifeSciences reported a net loss of $230.8 million for the full year 2025, with Q4 revenue reaching $49.9 million. Despite the losses, the company provided 2026 revenue guidance of $200 million to $210 million and Adjusted EBITDA guidance of $18 million to $20 million, signaling a focus on operational excellence and revenue growth. The firm also announced organizational restructuring and operating cost reductions.
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Maravai Lifesciences Holdings (MRVI) and Sarepta Therapeutics (SRPT)
This article provides analyst insights on three healthcare companies: Veracyte (VCYT), Maravai Lifesciences Holdings (MRVI), and Sarepta Therapeutics (SRPT). Veracyte received a reiterated Buy rating from William Blair and an upgrade to Buy from TipRanks – DeepSeek. Maravai Lifesciences Holdings maintained a Hold rating from Guggenheim and William Blair, while Sarepta Therapeutics received a Buy rating from Mizuho Securities.
Maravai LifeSciences Holdings (MRVI) Posts US$130.8m TTM Loss Challenging Margin Recovery Narratives
Maravai LifeSciences Holdings (MRVI) reported a US$130.8 million trailing twelve-month loss for FY 2025, with revenue of US$185.7 million, sparking concerns about its path to profitability. The company's recent quarterly losses and a five-year pattern of widening losses challenge narratives of margin recovery, despite management's efforts to implement over US$50 million in annualized cost savings. While the stock trades at a P/S of 2.8x, lower than peers, and has a DCF fair value of US$7.10 against a current price of US$3.56, analysts remain divided on its future prospects given its unprofitability and slower revenue growth compared to the US market.
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results
Maravai LifeSciences (NASDAQ: MRVI) reported its financial results for the fourth quarter and full year ended December 31, 2025, exceeding revenue expectations and returning to positive Adjusted EBITDA in Q4. The company announced quarterly revenue of $49.9 million and an annual revenue of $185.7 million, with a net loss of $(63.0) million and $(230.8) million respectively. Maravai also provided full-year 2026 guidance, projecting revenue between $200 million and $210 million and Adjusted EBITDA between $18 million and $20 million, driven by a focus on operational excellence and revenue growth.
Maravai LifeSciences (NASDAQ: MRVI) posts 2025 loss but targets 2026 EBITDA rebound
Maravai LifeSciences (NASDAQ: MRVI) reported a challenging 2025 with significant revenue decline and a net loss, primarily due to reduced demand for its CleanCap vaccine orders. Despite this, the company saw slightly positive Adjusted EBITDA in Q4 2025, driven by cost reductions. Looking ahead, Maravai projects a rebound in 2026, guiding for increased revenue and a return to positive Adjusted EBITDA, as it focuses on operational excellence and growth.
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results
Maravai LifeSciences (NASDAQ: MRVI) reported its fourth quarter and full year 2025 financial results, exceeding revenue expectations and returning to positive Adjusted EBITDA in Q4. The company announced full year 2026 revenue guidance of $200 million to $210 million and Adjusted EBITDA guidance of $18 million to $20 million, driven by operational excellence and cost reduction efforts. Financial performance was impacted by a decrease in TriLink revenue due to a lack of high-volume CleanCap orders, while Cygnus revenue saw an increase.
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Phibro Animal Health (PAHC) and Unicycive Therapeutics (UNCY)
This article summarizes recent analyst ratings for three healthcare companies. Stifel Nicolaus maintained a Buy rating for Thermo Fisher (TMO) with a $700 price target, while Bank of America Securities issued a Sell rating for Phibro Animal Health (PAHC) with a $32 price target. Noble Financial reiterated a Buy rating for Unicycive Therapeutics (UNCY) with a $60 price target, noting a significant potential upside.
Investor group (NASDAQ: MRVI) reports 7.23% Maravai LifeSciences stake
An investor group has filed an amended Schedule 13G/A, reporting a beneficial ownership of 10,486,451 Class A common shares, which represents 7.23% of Maravai LifeSciences Holdings, Inc. The group includes various entities like Hudson View Holdings LLC and JD Squared Holdings II LLC, along with individuals such as Stuart Feldman. The filing explicitly certifies that the shares were not acquired to change or influence the control of Maravai LifeSciences.
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Phibro Animal Health (PAHC) and Unicycive Therapeutics (UNCY)
Analysts have provided new ratings for several healthcare companies. Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Thermo Fisher (TMO) with a $700.00 price target, suggesting a strong upside. Bank of America Securities analyst Michael Ryskin maintained a Sell rating on Phibro Animal Health (PAHC), while Noble Financial's Robert LeBoyer reiterated a Buy rating on Unicycive Therapeutics (UNCY) with a significant price target of $60.00, implying a substantial upside.
Maravai LifeSciences Holdings (NASDAQ:MRVI shareholders incur further losses as stock declines 11% this week, taking five-year losses to 90%
Maravai LifeSciences Holdings (NASDAQ:MRVI) has seen its stock price drop by 90% over the last five years, including an 11% decline this past week and 32% over the last twelve months. The company is not currently profitable, and its revenue has shrunk by 21% per year over the last five years. Despite the poor financial performance, there has been some significant insider buying in the last three months, which could be a positive sign.
MRVI SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Maravai LifeSciences Holdings, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of investors who purchased shares between August 7, 2024, and February 24, 2025. The lawsuit alleges that Maravai made false and misleading statements regarding its revenue recognition, internal controls, and goodwill, leading to an overstatement of its financial prospects. Shareholders with losses during this period have until May 5, 2025, to seek appointment as lead plaintiff.
Maravai ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders. The investigation follows a class action complaint filed after Maravai announced errors in revenue recognition, a material weakness in internal controls, and a potential non-cash impairment charge related to a past acquisition, causing a significant drop in share price. The law firm is encouraging affected investors to contact them for more information.
A US$75m Market Cap Boost Pleasing ToMaravai LifeSciences Holdings Insiders
Maravai LifeSciences Holdings (NASDAQ:MRVI) experienced a 16% stock increase last week, adding US$75m to its market capitalization, which was pleasing for insiders who bought shares over the past year. Insiders, notably CEO Bernd Brust, collectively purchased US$1.9m worth of shares, indicating a positive outlook although the company did not make a profit in the last year. Insider ownership stands at 2.5%, aligning management's interests with smaller shareholders.
MRVI INVESTOR ALERT: Kirby McInerney LLP Reminds Maravai Lifesciences Holdings, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit
Kirby McInerney LLP is reminding investors of Maravai Lifesciences Holdings, Inc. (NASDAQ:MRVI) that the lead plaintiff deadline for a federal securities class action lawsuit is May 5, 2025. The lawsuit alleges that Maravai failed to disclose inadequate internal controls over revenue recognition and an overstatement of goodwill, leading to a significant stock price decline on February 25, 2025, after the company announced delays in its earnings release and annual report due to an identified error in revenue recognition and a potential non-cash impairment charge. Investors who purchased Maravai securities during the Class Period (August 7, 2024, through February 24, 2025) are encouraged to contact the law firm to discuss their rights.
